<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961541</url>
  </required_header>
  <id_info>
    <org_study_id>2019nCoV-ICC-E-101</org_study_id>
    <nct_id>NCT04961541</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine</brief_title>
  <official_title>A Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a Quadrivalent Hemagglutinin Nanoparticle Influenza and SARS-CoV-2 rS Nanoparticle Combination Vaccine With Matrix M1™ Adjuvant in Healthy Participants ≥ 50 to ≤ 70 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novavax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novavax</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and&#xD;
      immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle&#xD;
      combination vaccine with Matrix-M1 adjuvant; this combination is referred to as ICC vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with solicited local and systemic AE's</measure>
    <time_frame>Day 0 to Day 63</time_frame>
    <description>Numbers of participants with solicited local and systemic AEs over the 7 days post-injection after first and second doses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting all AE's</measure>
    <time_frame>Day 0 to Day 70</time_frame>
    <description>Percentage of participants reporting all AEs, solicited and unsolicited, over 70 days after the first dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with MAAE's, AESI's (including PIMMCs), SAEs</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>Percentage of participants with MAAEs, AESIs (including PIMMCs), SAEs, will be collected for 6 months (approximately 180 days) after the first dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B strain(s) expressed as GMT</measure>
    <time_frame>Day 56 to Day 180</time_frame>
    <description>HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B strain(s) calculated as GMT , defined as the antilog of the mean of the log-transformed HAI titers on Days 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B strain(s) expressed as (GMFRPost/Pre)</measure>
    <time_frame>Day 56 to Day 180</time_frame>
    <description>HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B strain(s) calculated as (GMFRPost/Pre), defined as the within-group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B strain(s) expressed as SCR</measure>
    <time_frame>Day 56 to Day 180</time_frame>
    <description>HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B strain(s) calculated as SCR defined as proportion of participants in a given treatment group with either a baseline reciprocal (Day 0) titer of &lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a baseline reciprocal (Day 0) titer of ≥ 10 and a post-vaccination titer ≥ 4-fold higher than the baseline titer as measured on Days 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a reciprocal HAI titer ≥ 40 expressed as SPR</measure>
    <time_frame>Day 56 to Day 180</time_frame>
    <description>Percentage of participants with a reciprocal HAI titer ≥ 40 on Days 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B strain(s) expressed as GMTR</measure>
    <time_frame>Day 56 to Day 180</time_frame>
    <description>GMT ratio (GMTR) between select treatment arms at Days 56, 70, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microneutralization (MN50) antibody responses expressed as GMT</measure>
    <time_frame>Day 56 to Day 180</time_frame>
    <description>Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B strain(s) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microneutralization (MN50) antibody responses expressed as GMFR</measure>
    <time_frame>Day 56 to Day 180</time_frame>
    <description>Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B strain(s) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMFR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microneutralization (MN50) antibody responses expressed as SCR</measure>
    <time_frame>Day 56 to Day 180</time_frame>
    <description>Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B strain(s) and/or antigenically-drifted influenza strains, as measured by a MN assay, expressed as SCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microneutralization (MN50) antibody responses expressed as GMTR</measure>
    <time_frame>Day 56 to Day 180</time_frame>
    <description>Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B strain(s) and/or antigenically-drifted influenza strains, as measured by a MN assay , expressed as GMTR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgG antibody concentrations as ELISA units to the SARS-CoV-2 spike protein expressed as GMEU</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgG antibody concentrations as ELISA units to the SARS-CoV-2 spike protein expressed as GMFR</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgG antibody concentrations as ELISA units to the SARS-CoV-2 spike protein expressed as SCR</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgG antibody concentrations as ELISA units to the SARS-CoV-2 spike protein expressed as GMEUR</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>IgG geometric mean ELISA unit concentrations (EU/mL) to the SARS-CoV-2 spike protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 expressed as GMT</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 expressed as GMFR</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 expressed as SCR</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN50 GMTs to the SARS-CoV-2 expressed as GMTR</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>MN50 GMTs to the SARS-CoV-2 from the matched vaccine construct (and mismatched variant if available), at Days 0, 56, 70, and other follow-up time points.</description>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">642</enrollment>
  <condition>SARS-CoV Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Group A - ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B -ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 2. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C - ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D - ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E - ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 4. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F- ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 5. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G- ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 6. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H- ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I- ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 8. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group J -ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 9. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K - ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 10. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group L - ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 11. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M -ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 12. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group N- ICC Vaccine Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group O - qNIV with Matrix-M1 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P- SARS-CoV-2 rS with Matrix-M1 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of Formulation 14. 1 dose each on Days 0 and Day 56.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ICC Vaccine</intervention_name>
    <description>Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.</description>
    <arm_group_label>Group A - ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group B -ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group C - ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group D - ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group E - ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group F- ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group G- ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group H- ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group I- ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group J -ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group K - ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group L - ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group M -ICC Vaccine Formulation</arm_group_label>
    <arm_group_label>Group N- ICC Vaccine Formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant</intervention_name>
    <description>Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.</description>
    <arm_group_label>Group O - qNIV with Matrix-M1 adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant</intervention_name>
    <description>Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.</description>
    <arm_group_label>Group P- SARS-CoV-2 rS with Matrix-M1 adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Healthy, medically stable adult males or females ≥ 50 to ≤ 70 years of age at&#xD;
             screening.&#xD;
&#xD;
          2. Willing and able to give informed consent prior to study enrollment.&#xD;
&#xD;
          3. Able to attend study visits, comply with study requirements, and provide reliable and&#xD;
             complete reports of AEs.&#xD;
&#xD;
          4. Participants must have been baseline seropositive to SARS-CoV-2 defined as either:&#xD;
&#xD;
             • Having completed a primary vaccination series against SARS-CoV-2 with an authorized&#xD;
             COVID-19 vaccine with receipt of second/final dose of authorized vaccine ≥ 8 weeks&#xD;
             prior to enrollment (first study vaccination).&#xD;
&#xD;
             OR&#xD;
&#xD;
             • Previously infected with SARS CoV-2 ≥ 8 weeks prior to enrollment (first study&#xD;
             vaccination).&#xD;
&#xD;
             Note: Baseline SARS-CoV-2 serostatus determination at screening will be based on&#xD;
             vaccination documentation (eg, vaccination card or vaccination registry) or&#xD;
             participants' report of a previous SARS-CoV-2 infection.&#xD;
&#xD;
          5. Women of childbearing potential (defined as any female participant who is NOT&#xD;
             surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral&#xD;
             oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive&#xD;
             months]) must agree to be heterosexually inactive from at least 28 days prior to&#xD;
             enrollment and through the end of the study OR agree to consistently use a medically&#xD;
             acceptable method of contraception listed below from at least 28 days prior to&#xD;
             enrollment and through the end of the study.&#xD;
&#xD;
               1. Condoms (male or female) with spermicide (if acceptable in-country)&#xD;
&#xD;
               2. Diaphragm with spermicide&#xD;
&#xD;
               3. Cervical cap with spermicide&#xD;
&#xD;
               4. Intrauterine device&#xD;
&#xD;
               5. Oral or patch contraceptives&#xD;
&#xD;
               6. Norplant®, Depo-Provera®, or other in-country regulatory approved contraceptive&#xD;
                  method that is designed to protect against pregnancy&#xD;
&#xD;
               7. Abstinence, as a form of contraception, is acceptable if in line with the&#xD;
                  participant's lifestyle&#xD;
&#xD;
          6. Participants must be healthy and medically stable, as determined by the investigator&#xD;
             (based on a review of health status, vital signs [to include body temperature],&#xD;
             medical history, and targeted physical examination [to include body weight]).&#xD;
             Participants must have a body mass index (BMI) of 17 to 34 kg/m2, inclusive, at&#xD;
             screening. Vital signs must be within medically acceptable ranges prior to the first&#xD;
             vaccination.&#xD;
&#xD;
          7. Participants must agree to not participate in any other SARS-CoV-2 or influenza&#xD;
             prevention or treatment studies for the duration of the study. Note: For participants&#xD;
             who become hospitalized with COVID-19, participation in investigational treatment&#xD;
             studies is permitted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any ongoing, symptomatic acute, or chronic illness requiring medical or surgical care.&#xD;
&#xD;
               -  Asymptomatic chronic conditions or findings (eg, mild hypertension, dyslipidemia)&#xD;
                  that are not associated with evidence of end-organ damage are not exclusionary&#xD;
                  provided that they are being appropriately managed and are clinically stable (ie,&#xD;
                  unlikely to result in symptomatic illness within the time-course of this study),&#xD;
                  in the opinion of the investigator.&#xD;
&#xD;
               -  Acute or chronic illnesses or conditions which may be reasonably predicted to&#xD;
                  become symptomatic if treatment were withdrawn or interrupted are exclusionary,&#xD;
                  even if stable.&#xD;
&#xD;
               -  Acute or chronic illnesses reasonably expected to be associated with increased&#xD;
                  risks in the event of influenza or SARS-CoV-2 infection (eg, cardio-pulmonary&#xD;
                  diseases, diabetes mellitus, renal or hepatic dysfunction, hemoglobinopathies)&#xD;
                  are exclusionary, even if stable.&#xD;
&#xD;
          2. Participation in research involving an investigational product (drug/biologic/device)&#xD;
             within 90 days before the planned date of the first injection.&#xD;
&#xD;
          3. Use of COVID-19 prophylactic or treatment monoclonal antibodies or antibody cocktails&#xD;
             within 90 days prior to the planned date of the first injection.&#xD;
&#xD;
          4. History of a serious reaction to prior influenza vaccination or known allergy to&#xD;
             constituents of influenza vaccines - including egg proteins - or polysorbate 80; or&#xD;
             any known allergies to products contained in the investigational product.&#xD;
&#xD;
          5. Any history of anaphylaxis to any prior vaccine.&#xD;
&#xD;
          6. History of Guillain-Barré Syndrome within 6 weeks following a previous influenza&#xD;
             vaccine.&#xD;
&#xD;
          7. Receipt of any vaccine in the 4 weeks preceding the study vaccination and any&#xD;
             influenza vaccine within 2 months preceding the study vaccination. Note: Routine&#xD;
             vaccinations will not be allowed until after study Day 70.&#xD;
&#xD;
          8. Any known or suspected autoimmune or immunosuppressive illness, congenital or&#xD;
             acquired, based on medical history and/or physical examination.&#xD;
&#xD;
          9. Chronic administration (defined as more than 14 continuous days) of immunosuppressants&#xD;
             or other immune-modifying drugs within 6 months prior to the administration of the&#xD;
             study vaccines. An immunosuppressant dose of glucocorticoid will be defined as a&#xD;
             systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical,&#xD;
             inhaled, and nasal glucocorticoids will be permitted.&#xD;
&#xD;
         10. Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the administration of the study vaccine or during the study.&#xD;
&#xD;
         11. Active cancer (malignancy) therapy within 3 years prior to first study vaccination&#xD;
             (with the exception of adequately treated non-melanomatous skin carcinoma or lentigo&#xD;
             maligna and uterine cervical carcinoma in situ without evidence of disease, at the&#xD;
             discretion of the investigator).&#xD;
&#xD;
         12. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to&#xD;
             the EoS.&#xD;
&#xD;
         13. Known disturbance of coagulation.&#xD;
&#xD;
         14. Suspected or known history of alcohol abuse or drug addiction within 2 years prior to&#xD;
             the first trial vaccine dose that, in the opinion of the investigator, might interfere&#xD;
             with protocol compliance.&#xD;
&#xD;
         15. Acute disease at the time of enrollment (defined as the presence of a moderate or&#xD;
             severe illness with or without fever, or an oral temperature &gt; 38.0°C, on the planned&#xD;
             day of vaccine administration).&#xD;
&#xD;
         16. Any condition that in the opinion of the investigator would pose a health risk to the&#xD;
             participant if enrolled or could interfere with evaluation of the vaccine or&#xD;
             interpretation of study results (including neurologic or psychiatric conditions deemed&#xD;
             likely to impair the quality of safety reporting).&#xD;
&#xD;
         17. Study team member or immediate family member of any study team member (inclusive of&#xD;
             Sponsor, Contract Research Organization, and study site personnel involved in the&#xD;
             conduct or planning of the study).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Shinde, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novavax</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paratus Clinical Research - Canberra</name>
      <address>
        <city>Bruce</city>
        <state>Australian Capital Territory</state>
        <zip>2617</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Research - Western Sydney</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Beaches Clinical Research</name>
      <address>
        <city>Brookvale</city>
        <state>New South Wales</state>
        <zip>2100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Research - Central Coast</name>
      <address>
        <city>Kanwal</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunter Diabetes Centre</name>
      <address>
        <city>Merewether</city>
        <state>New South Wales</state>
        <zip>2291</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Sunshine Coast,Southbank</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Sunshine Coast, Health Hub Morayfield</name>
      <address>
        <city>Morayfield</city>
        <state>Queensland</state>
        <zip>4506</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Sunshine Coast</name>
      <address>
        <city>Sippy Downs</city>
        <state>Queensland</state>
        <zip>4556</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austrials Pty Ltd - Taringa</name>
      <address>
        <city>Taringa</city>
        <state>Queensland</state>
        <zip>4068</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3214</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

